Key result
Atorvastatin plus ezetimibe shows moderate aortic lesion regression in a 7-year-old with HoFH despite elevated LDL.
Why the study?
Homozygous familial hypercholesterolemia is a rare, severe form manifesting in early childhood with extremely high LDL-cholesterol and early-onset atherosclerosis, requiring early diagnosis and management.
Does atorvastatin and ezetimibe improve atheromatous lesions in a child with homozygous familial hypercholesterolemia?
Case Report (n=1)
Does atorvastatin and ezetimibe improve atheromatous lesions in a child with homozygous familial hypercholesterolemia?
Early screening and intensive lipid-lowering therapy can lead to regression of atheromatous lesions in children with homozygous familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
May support early intensive therapy in pediatric HoFH; single-case observation leaves efficacy and generalizability unproven.
Familial hypercholesterolemia (FH) is a common autosomal dominant disorder characterized by markedly elevated low-density lipoprotein (LDL)-cholesterol levels and an increased risk of premature cardiovascular disease. The homozygous form, which is much rarer and more severe, manifests in early childhood with extremely high LDL-cholesterol levels and early-onset atherosclerosis. We report the case of a seven-year-old girl, born to consanguineous parents, presenting with tuberous and tendinous xanthomas. Her lipid profile revealed severe hypercholesterolemia (total cholesterol: 7.5 g/L; LDL-C: 6.82 g/L), low high-density lipoprotein-cholesterol (HDL-C) (0.29 g/L), and normal triglycerides. Echocardiography showed atheromatous lesions in the aortic arch. Molecular analysis identified a pathogenic homozygous mutation in the LDLR gene. Treatment with atorvastatin followed by ezetimibe was initiated, along with dietary and lifestyle modifications. Follow-up showed moderate regression of the atheromatous lesions. A six-month follow-up plan was established, and LDL apheresis was considered. This case highlights the importance of early screening, genetic confirmation, and intensive multidisciplinary management to prevent premature cardiovascular complications in children with homozygous familial hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Bensabbahia et al. (2025) conducted a case report in Homozygous Familial Hypercholesterolemia (n=1). Atorvastatin and ezetimibe was evaluated on Lipid levels and atheromatous lesion regression. Treatment with atorvastatin and ezetimibe in a 7-year-old girl with homozygous familial hypercholesterolemia led to moderate regression of aortic atheromatous lesions, though LDL levels remained elevated.
Synapse has enriched 10 related papers. Consider them for comparative context: